GLAND2024-10-012024-12-31 GLAND2024-10-012024-12-31 GLAND2024-10-012024-12-31in-bse-fin:OneOperatingExpenses01Member GLAND2024-10-012024-12-31in-bse-fin:OneOperatingExpenses02Member GLAND2024-10-012024-12-31in-bse-fin:FourOperatingExpenses01Member GLAND2024-10-012024-12-31in-bse-fin:FourOperatingExpenses02Member GLAND2024-12-31 iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 543245 GLAND NOTLISTED Gland Pharma Limited Equity 2024-04-01 2025-03-31 2025-02-03 2025-01-16 INR Millions Third quarter 15:00:00 17:00:00 2025-02-03 2025-02-03 Not applicable Single segment Pharmaceuticals 2024-10-01 2024-12-31 Unaudited Standalone 10107820000.00 650640000.00 10758460000.00 3489100000.00 21470000.00 255280000.00 1053630000.00 183080000.00 437670000.00 1376920000.00 6817150000.00 3941310000.00 0.00 3941310000.00 950920000.00 39160000.00 990080000.00 0.00 2951230000.00 0.00 0.00 0.00 0.00 2951230000.00 5550000.00 2956780000.00 2956780000.00 0.00 164750000.00 1 17.91 17.91 0.00 0.00 17.91 17.91 1. In terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this Statement of Unaudited Standalone Financial Results for the quarter and nine months ended December 31, 2024 ( Unaudited Standalone Financial Results ) of the Company has been reviewed by the Audit Committee and approved by the Board of Directors at their meetings held on February 3, 2025.The statutory auditors have carried out a limited review on the Unaudited Standalone Financial Results and issued an unmodified report thereon. 2. The Unaudited Standalone Financial Results of the Company have been prepared in accordance with the Indian Accounting Standards notified under Section 133 of the Companies Act 2013, as amended and read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the Listing requirements ). 3. The Company is engaged in the manufacture and sale of Pharmaceuticals which constitutes a single reportable business segment as per Ind AS 108- 'Operating Segments'. Refer the signed results uploaded for the complete notes. Single segment 2024-04-01 2024-12-31 Unaudited Standalone 30857960000.00 1713570000.00 32571530000.00 11164650000.00 113890000.00 1975270000.00 3193280000.00 193910000.00 1261990000.00 3925920000.00 21828910000.00 10742620000.00 0.00 10742620000.00 2676360000.00 68720000.00 2745080000.00 0.00 7997540000.00 0.00 0.00 0.00 0.00 7997540000.00 16670000.00 8014210000.00 8014210000.00 0.00 164750000.00 1 48.55 48.54 0.00 0.00 48.55 48.54 Other expenses 1054310000.00 Power and fuel 322610000.00 Other expenses 3008370000.00 Power and fuel 917550000.00 7420000.00 22280000.00 1870000.00 5610000.00 0.00 0.00